New variation of CAR T-cell therapy holds promise for leukemia – domain-B
|
New variation of CAR T-cell therapy holds promise for leukemia
domain-B Scientists at Stanford University have identified a molecule that can be targeted to cure leukaemia – the most common form of cancer in childhood. The therapy is similar to but distinct from CD19-targeted chimeric antigen receptor T-cell therapy, or … |
